drugset / Trial / NCT01531517

Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers

NCT01531517

Phase 3 Terminated 47 enrolled European Egyptian Pharmaceutical Industries
RandomizedParallel-groupOpen-labelTreatment

Summary

Clinical Trial Phase III-b Study Sponsor: European Egyptian Pharmaceutical Industries Sample Size: 120 patients (60 per arm) Study Population: Patients with Diabetic foot ulcer of any stage after proper surgical treatment - if needed. Those patients will be recruited from patients attending the Diabetic foot Center at Faculty of Medicine - Alexandria University and the outpatient clinic at Faculty of Medicine, Cairo University. Recruitment Period: 9 months Dose application: thick layer of 2-3 mm applied to the dressing then dressing applied to the ulcer. Endpoints: Complete healing of the ulcer OR 5 months of application of the ointment whichever comes first

Timeline

Start
2011-07
Primary completion
2012-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Panthenol Unknown Topical

Indications